Philip D King, PhD

 Philip D. King
Professor of Microbiology and Immunology
Medical School
Office:
University of Michigan Medical School
Microbiology and Immunology
1150 West Medical Center Drive
Ann Arbor, MI 487109
Email:
[email protected]
Phone:
Available to mentor
Philip D King, PhD
Philip D. King
Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Dr. King obtained his Ph.D. in immunology from University College London. He performed postdoctoral work in immunology and intracellular signal transduction at Memorial Sloan Kettering Cancer Center in New York City before establishing his own laboratory at Cornell University Medical Center, also in New York City. In 2003, he joined the Department of Microbiology and Immunology at the University of Michigan Medical School.

    Qualifications
    • PhD
      University College London, London, England, United Kingdom
      1986 - 1991
    • BSc
      University of Glasgow, Glasgow, Scotland, United Kingdom
      1982 - 1986

    Center Memberships
    • Center Member
      Center for Cell Plasticity and Organ Design

    Research Overview

    Research in the King laboratory aims to understand mechanisms of receptor-induced intracellular signaling in mammals. We are also interested in how inherited and acquired mutations in genes that encode different signaling pathway components result in disease and how dysregulated signaling can be controlled to therapeutic benefit. To interrogate signaling pathways, we employ various techniques, including conditional gene targeting, which permits an understanding of receptor signal transduction in physiological contexts. Most of the genes that have been targeted encode regulators of the ubiquitous Ras signaling pathway. They include non-receptor protein tyrosine phosphatases, intracellular adapter proteins, and Ras GTPase-activating proteins that act upstream and downstream of the Ras small GTP-binding protein that is the nodal point in this pathway. The phenotypes that have emerged in these mice illustrate the complexity of mechanisms by which Ras activation is controlled and how these mechanisms vary between different cell types and tissues. Furthermore, several of the generated models have provided insight into mechanisms of inherited genetic diseases in man. A current major interest of the laboratory is understanding how the Ras signaling pathway regulates blood and lymphatic vascular development and function. Furthermore, we have a long-standing interest in how this pathway regulates T-cell development and function.

    Recent Publications

     See All Publications
    • Journal Article
      The C2 domain augments Ras GTPase-activating protein catalytic activity
      Paul ME, Chen D, Vish KJ, Lartey NL, Hughes E, Freeman ZT, Saunders TL, Stiegler AL, King PD, Boggon TJ. Proceedings of the National Academy of Sciences of the United States of America, 2025 Feb 11; 122 (6): DOI:10.1073/pnas.2418433122
      PMID: 39899710
    • Journal Article
      Transport and Immune Functions of the Lymphatic System
      Davis MJ, Zawieja SD, King PD. Annual Review of Physiology, 2025 Feb 10; 87 (1): 151 - 172. DOI:10.1146/annurev-physiol-022724-104908
      PMID: 39441893
    • Journal Article
      EPHB4-RASA1 Inhibition of PIEZO1 Ras Activation Drives Lymphatic Valvulogenesis
      Chen D, Tang Y, Lapinski PE, Wiggins D, Sevick EM, Davis MJ, King PD. Circulation Research, 2024 Nov 8; 135 (11): 1048 - 1066. DOI:10.1161/CIRCRESAHA.124.325383
      PMID: 39421925
    • Journal Article
      Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations
      Zhao S, Mekbib KY, van der Ent MA, Allington G, Prendergast A, Chau JE, Smith H, Shohfi J, Ocken J, Duran D, Furey CG, Hao LT, Duy PQ, Reeves BC, Zhang J, Nelson-Williams C, Chen D, Li B, Nottoli T, Bai S, Rolle M, Zeng X, Dong W, Fu PY, Wang YC, Mane S, Piwowarczyk P, Fehnel KP, See AP, Iskandar BJ, Aagaard-Kienitz B, Moyer QJ, Dennis E, Kiziltug E, Kundishora AJ, DeSpenza T, Greenberg ABW, Kidanemariam SM, Hale AT, Johnston JM, Jackson EM, Storm PB, Lang SS, Butler WE, Carter BS, Chapman P, Stapleton CJ, Patel AB, Rodesch G, Smajda S, Berenstein A, Barak T, Erson-Omay EZ, Zhao H, Moreno-De-Luca A, Proctor MR, Smith ER, Orbach DB, Alper SL, Nicoli S, Boggon TJ, Lifton RP, Gunel M, King PD, Jin SC, Kahle KT. Nature Communications, 2023 Dec 1; 14 (1): DOI:10.1038/s41467-023-43062-z
      PMID: 37978175
    • Journal Article
      Cutting Edge: Induced Loss of Rasgrp1 in Peripheral CD41 T Cells of Conditional Rasgrp1-Deficient Mice Reveals an Essential Role for Rasgrp1 in TCR/CD28-Induced Ras-MAPK Signaling
      Chang Y, Manivannan P, Doosti A, Lapinski PE, Chen D, Roose JP, King PD. Journal of Immunology, 2023 Sep 15; 211 (6): 917 - 922. DOI:10.4049/jimmunol.2300138
      PMID: 37566514
    • Journal Article
      Angiogenesis depends upon EPHB4-mediated export of collagen IV from vascular endothelial cells
      Chen D, Hughes ED, Saunders TL, Wu J, Hernandez Vasquez MN, Makinen T, King PD. Jci Insight, 2022 Feb 22; 7 (4): DOI:10.1172/jci.insight.156928
      PMID: 35015735
    • Journal Article
      Macropinocytosis drives T cell growth by sustaining the activation of mTORC1
      Charpentier JC, Chen D, Lapinski PE, Turner J, Grigorova I, Swanson JA, King PD. Nature Communications, 2020 Dec 1; 11 (1): DOI:10.1038/s41467-019-13997-3
      PMID: 31924779
    • Journal Article
      RASA1-driven cellular export of collagen IV is required for the development of lymphovenous and venous valves in mice
      Chen D, Geng X, Lapinski PE, Davis MJ, Srinivasan RS, King PD. Development Cambridge, 2020 Dec 1; 147 (23): DOI:10.1242/dev.192351
      PMID: 33144395